Tyenne Injection 400 mg/20 mL vial
Product details
- Tyenne Injection 400 mg/20 mL vial
Company announcement
Fresenius Kabi is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials nationwide, as announced on August 10, 2026, due to the presence of glass particles.
The product was distributed to wholesalers, distributors, and direct customers across the United States.
The document does not mention any reported deaths or injuries related to this recall.
Risk:
The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More seriously, glass particles can cause blockage and clotting in blood vessels, which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death.
Impacted states: Nationwide
Products:
- Tyenne® (tocilizumab-aazg) Injection, 400 mg / 20 mL (20mg/mL) 20 mL vial
Contact
For more information, call (800) 551-7176 or email productcomplaint.USA@fresenius-kabi.com.
Related recalls
- Argatroban Injection 250 mg/2.5 mL (100 mg/mL)
- Brevital Sodium 500 mg/vial for Injection
- Glutathione Injection
- Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) for Intravenous Infusion
- 0.9% Sodium Chloride Injection, USP, 100 mL
- Compounded Glutathione 200 mg/mL 30 mL multidose vial; Myer’s Cocktail 30 mL multidose vial; Tri-Immune Boost 30 mL multidose vial